Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Strategic Expansion | Learn about Immunovant's ambitious plan to target 10 indications by 2026, potentially diversifying risk and expanding market reach |
Financial Outlook | Analysts set price targets ranging from $36 to $58, suggesting significant upside potential despite recent stock price decline |
Market Opportunity | Explore the substantial market for Graves' disease treatment, with an estimated 20,000 high-need patients diagnosed annually in the US |
Promising Pipeline | Immunovant's anti-FcRn therapy shows potential in treating Graves' disease and other autoimmune conditions, with impressive IgG reduction capabilities |
Metrics to compare | IMVT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMVTPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.5x | −4.7x | −0.5x | |
PEG Ratio | 0.14 | 0.08 | 0.00 | |
Price / Book | 3.8x | 5.9x | 2.6x | |
Price / LTM Sales | - | 9.2x | 3.0x | |
Upside (Analyst Target) | 184.8% | 195.9% | 52.6% | |
Fair Value Upside | Unlock | 14.5% | 8.7% | Unlock |